Compositions and methods for improving mitochondrial function and treating neurodegenerative diseases and cognitive disorders

Patent metadata

Field	Value
Publication number	US-10028932-B2
Application number	US-201514656096-A
Country	US
Kind code	B2
Filing date	Mar 12, 2015
Priority date	Dec 23, 2010
Publication date	Jul 24, 2018
Grant date	Jul 24, 2018

Abstract

Provided are compositions comprising compounds or precursors to compounds which may be used for a variety of therapeutic applications including, for example, treating and/or preventing a disease or disorder related to reduced or inadequate mitochondrial activity, including aging or stress, diabetes, obesity, and neurodegenerative diseases. The compounds relate generally to urolithins and precursors thereof, including but not limited to ellagitannins and urolithin A. In certain embodiments the compositions are presented in or as food products or nutritional supplements. These same compounds and compositions can also be used advantageously in generally healthy individuals to increase or maintain metabolic rate, decrease percent body fat, increase or maintain muscle mass, manage body weight, improve or maintain mental performance (including memory), improve or maintain muscle performance, improve or maintain mood, and manage stress.

First claim

We claim:

1. A method of treating a muscular or neuromuscular disease, comprising:
administering to a subject in need thereof a therapeutically effective amount of a urolithin thereby treating the muscular or neuromuscular disease.

2. The method of claim 1 , wherein the muscular or neuromuscular disease is a myopathy.

3. The method of claim 1 , wherein the muscular or neuromuscular disease is a muscular dystrophy.

4. The method of claim 1 , wherein the muscular or neuromuscular disease is Duchenne muscular dystrophy.

5. The method of claim 1 , wherein the muscular or neuromuscular disease is mitochondrial myopathy.

6. The method of claim 1 , wherein the urolithin is selected from the group consisting of urolithin A, urolithin B, and a combination of urolithin A and urolithin B.

7. The method of claim 1 , wherein the urolithin is urolithin A.

8. The method of claim 1 , wherein the urolithin is urolithin B.

9. The method of claim 1 , wherein the urolithin is urolithin C.

10. The method of claim 1 , wherein the urolithin is urolithin D.

11. The method of claim 1 , wherein the urolithin is administered orally.

12. The method of claim 1 , wherein the urolithin is administered parenterally.

13. The method of claim 1 , wherein the urolithin is administered at least weekly.

14. The method of claim 1 , wherein the urolithin is administered at least daily.

15. The method of claim 7 , wherein the muscular or neuromuscular disease is a myopathy.

16. The method of claim 7 , wherein the muscular or neuromuscular disease is a muscular dystrophy.

17. The method of claim 7 , wherein the muscular or neuromuscular disease is Duchenne muscular dystrophy.

18. The method of claim 7 , wherein the muscular or neuromuscular disease is mitochondrial myopathy.

19. The method of claim 8 , wherein the muscular or neuromuscular disease is a myopathy.

20. The method of claim 8 , wherein the muscular or neuromuscular disease is a muscular dystrophy.

21. The method of claim 8 , wherein the muscular or neuromuscular disease is Duchenne muscular dystrophy.

22. The method of claim 8 , wherein the muscular or neuromuscular disease is mitochondrial myopathy.

23. The method of claim 1 , wherein the subject is a human.

24. The method of claim 2 , wherein the subject is a human.

25. The method of claim 3 , wherein the subject is a human.

26. The method of claim 4 , wherein the subject is a human.

27. The method of claim 5 , wherein the subject is a human.

28. The method of claim 7 , wherein the subject is a human.

29. The method of claim 8 , wherein the subject is a human.

30. The method of claim 15 , wherein the subject is a human.

31. The method of claim 16 , wherein the subject is a human.

32. The method of claim 17 , wherein the subject is a human.

33. The method of claim 18 , wherein the subject is a human.

34. The method of claim 1 , wherein the urolithin is administered in the form of a pharmaceutical.

35. The method of claim 1 , wherein the urolithin is administered in the form of a medical food.

36. The method of claim 1 , wherein the urolithin is administered in the form of a functional food.

37. The method of claim 1 , wherein the urolithin is administered in the form of a food additive.

38. The method of claim 1 , wherein the urolithin is administered in the form of a dietary supplement.

39. The method of claim 1 , wherein the urolithin is administered in the form of a food product.

40. The method of claim 1 , wherein the urolithin is administered in the form of a nutritional supplement.

Assignees

• Amazentis Sa

Inventors

• Rinsch Christopher L
• Blanco-Bose William
• Schneider Bernard
• Thomas Charles
• Sandi Carmen
• Auwerx Johan
• Andreux Penelope
• Houtkooper Richardus
• Pirinen Eija
• Mouchiroud Laurent
• Genoux David

Classifications

• A61P43/00

  Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00 · CPC title

• A61P9/10

  for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis · CPC title

• A61P9/00

  Drugs for disorders of the cardiovascular system · CPC title

• A61P7/02

  Antithrombotic agents; Anticoagulants; Platelet aggregation inhibitors · CPC title

• A61P7/00

  Drugs for disorders of the blood or the extracellular fluid · CPC title